SPVN-06

N/A

Report date: 2023/10/26 17:03:07

Base Information

Drug NameSPVN-06

Drug Alias NameNXNL1 gene therapy encoding RdCVF and RdCVFLadeno-associated virus (AAV) vector gene therapynucleoredoxin-like 1 (NXNL1) gene therapy encoding RdCVF and RdCVFL

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionNXNL1 gene transference

TargetsNucleoredoxin-like protein 1

Therapy Area/IndicationsRetinitis PigmentosaCone-Rod Dystrophies

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSparingVision Inc

China Registration ClassN/A

Develop Information

Active CompaniesSparingVision Inc

Inactive CompaniesN/A

Active IndicationsRetinitis PigmentosaCone-Rod Dystrophies

Inactive IndicationsN/A

Other Information

ATC CodeN/A